Technical analysis of Editas Medicine, Inc. (EDIT): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia.
Price Performance
| 1 month | -5.90% |
| 3 months | +0.74% |
| Year-to-date | +32.20% |
| 1 year | -0.37% |
| 3 years | -66.17% |
| 5 years | -95.71% |
52-Week Range
| 52-week High | $4.54 |
| 52-week Low | $1.66 |
| Avg Volume (90d) | 2.5M |
Technical Indicators
| SMA 50 | $2.93 |
| SMA 200 | $2.62 |
| Beta | 2.04 |
| 30-day Volatility (annualised) | 76.4% |
| Price vs SMA 50 | -7.4% |
| Price vs SMA 200 | +3.3% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $3.08 | |
| 2025-11 | $2.41 | -21.8% |
| 2025-12 | $2.05 | -14.9% |
| 2026-01 | $1.99 | -2.9% |
| 2026-02 | $2.20 | +10.6% |
| 2026-03 | $2.47 | +12.3% |
| 2026-04 | $3.00 | +21.5% |
| 2026-05 | $3.46 | +15.3% |
| 2026-06 | $3.24 | -6.4% |
| 2026-07 | $2.58 | -20.4% |
| 2026-08 | $3.06 | +18.6% |
| 2026-09 | $2.71 | -11.4% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | | |
| 2026-09-14 | | $563M |
| 2026-09-14 | | |
| 2026-09-14 | | $159M |
| 2026-09-14 | $0.20 | $23M |
| 2026-09-14 | | |
Price
| Price | $2.71 |
| Market Cap | $416M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.88 |
| EV / EBITDA | -4.25 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.15 |
| Current Ratio | 3.19 |